Author

C. J. Giuliano

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

B. S. Waldman· 2 shared S. Lourido· 2 shared A. C. Palladino· 1 shared A. G. Sanderlin· 1 shared A. L. Herneisen· 1 shared A. Lin· 1 shared C. A. Hunter· 1 shared E. A. Boydston· 1 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

B. S. Waldman

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologybioRxivPreprintMar 5, 2023

Functional profiling of the Toxoplasma genome during acute mouse infection

C. J. Giuliano, K. J. Wei, F. M. Harling…·S. Lourido

The paper uses CRISPR screens to identify 300+ genes in Toxoplasma gondii that affect parasite fitness in mice, revealing new roles in host-parasite interactions and potential drug targets.

DOI 10.1101/2023.03.05.531216

mousegenetic perturbation / CRISPR

𝕏 PostBluesky

MicrobiologybioRxivApr 6, 2022

A positive feedback loop controls Toxoplasma chronic differentiation

M. H. Licon, C. J. Giuliano, S. Chakladar…·S. Lourido

The paper identifies a positive feedback loop between BFD1 and BFD2 that drives Toxoplasma gondii chronic differentiation.

DOI 10.1038/s41564-023-01358-2

experimental assaycell type annotation

𝕏 PostBluesky

Cancer BiologybioRxivOct 16, 2017

Combining CRISPR/Cas9 mutagenesis and a small-molecule inhibitor to probe the function of MELK in cancer

C. J. Giuliano, A. Lin, J. C. Smith…·J. M. Sheltzer

This study uses CRISPR/Cas9 and a MELK inhibitor to show that MELK knockout cancer cells grow normally, suggesting anti-MELK therapies may not be effective as monotherapies.

DOI 10.7554/elife.32838

humanbulk RNA-seq

𝕏 PostBluesky